Logo image of MRNA

MODERNA INC (MRNA) Stock Fundamental Analysis

NASDAQ:MRNA - Nasdaq - US60770K1079 - Common Stock - Currency: USD

27.99  +1.6 (+6.06%)

Premarket: 28.15 +0.16 (+0.57%)

Fundamental Rating

3

Taking everything into account, MRNA scores 3 out of 10 in our fundamental rating. MRNA was compared to 561 industry peers in the Biotechnology industry. While MRNA seems to be doing ok healthwise, there are quite some concerns on its profitability. MRNA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MRNA had negative earnings in the past year.
In the past year MRNA has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: MRNA reported negative net income in multiple years.
In multiple years MRNA reported negative operating cash flow during the last 5 years.
MRNA Yearly Net Income VS EBIT VS OCF VS FCFMRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

MRNA has a better Return On Assets (-26.42%) than 70.23% of its industry peers.
The Return On Equity of MRNA (-33.35%) is better than 74.51% of its industry peers.
Industry RankSector Rank
ROA -26.42%
ROE -33.35%
ROIC N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
MRNA Yearly ROA, ROE, ROICMRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

With an excellent Gross Margin value of 68.68%, MRNA belongs to the best of the industry, outperforming 81.11% of the companies in the same industry.
In the last couple of years the Gross Margin of MRNA has declined.
The Profit Margin and Operating Margin are not available for MRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
MRNA Yearly Profit, Operating, Gross MarginsMRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRNA has more shares outstanding
MRNA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MRNA has been reduced compared to a year ago.
MRNA Yearly Shares OutstandingMRNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
MRNA Yearly Total Debt VS Total AssetsMRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

An Altman-Z score of 3.35 indicates that MRNA is not in any danger for bankruptcy at the moment.
The Altman-Z score of MRNA (3.35) is better than 75.94% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that MRNA is not too dependend on debt financing.
MRNA has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.35
ROIC/WACCN/A
WACC9.91%
MRNA Yearly LT Debt VS Equity VS FCFMRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

MRNA has a Current Ratio of 4.22. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
MRNA has a Current ratio (4.22) which is comparable to the rest of the industry.
MRNA has a Quick Ratio of 4.14. This indicates that MRNA is financially healthy and has no problem in meeting its short term obligations.
MRNA has a Quick ratio (4.14) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.22
Quick Ratio 4.14
MRNA Yearly Current Assets VS Current LiabilitesMRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

6

3. Growth

3.1 Past

MRNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.29%, which is quite impressive.
Looking at the last year, MRNA shows a very negative growth in Revenue. The Revenue has decreased by -38.35% in the last year.
Measured over the past years, MRNA shows a very strong growth in Revenue. The Revenue has been growing by 122.01% on average per year.
EPS 1Y (TTM)44.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.92%
Revenue 1Y (TTM)-38.35%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-35.33%

3.2 Future

The Earnings Per Share is expected to grow by 18.49% on average over the next years. This is quite good.
MRNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.30% yearly.
EPS Next Y-12.35%
EPS Next 2Y6.46%
EPS Next 3Y13.02%
EPS Next 5Y18.49%
Revenue Next Year-34.88%
Revenue Next 2Y-15.76%
Revenue Next 3Y-4.3%
Revenue Next 5Y20.3%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MRNA Yearly Revenue VS EstimatesMRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
MRNA Yearly EPS VS EstimatesMRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRNA Price Earnings VS Forward Price EarningsMRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRNA Per share dataMRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

MRNA's earnings are expected to grow with 13.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.46%
EPS Next 3Y13.02%

More info and screens

0

5. Dividend

5.1 Amount

MRNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MODERNA INC

NASDAQ:MRNA (5/20/2025, 8:18:16 PM)

Premarket: 28.15 +0.16 (+0.57%)

27.99

+1.6 (+6.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners73.88%
Inst Owner Change2.19%
Ins Owners5.45%
Ins Owner Change0.06%
Market Cap10.82B
Analysts64.24
Price Target46.68 (66.77%)
Short Float %16.8%
Short Ratio6.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.48%
Min EPS beat(2)-6.26%
Max EPS beat(2)21.22%
EPS beat(4)3
Avg EPS beat(4)30%
Min EPS beat(4)-6.26%
Max EPS beat(4)101.54%
EPS beat(8)6
Avg EPS beat(8)-10.14%
EPS beat(12)8
Avg EPS beat(12)-0.55%
EPS beat(16)11
Avg EPS beat(16)3.53%
Revenue beat(2)1
Avg Revenue beat(2)0.08%
Min Revenue beat(2)-0.3%
Max Revenue beat(2)0.45%
Revenue beat(4)3
Avg Revenue beat(4)31.23%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)78.74%
Revenue beat(8)7
Avg Revenue beat(8)29.59%
Revenue beat(12)9
Avg Revenue beat(12)24.91%
Revenue beat(16)12
Avg Revenue beat(16)19.49%
PT rev (1m)-12.16%
PT rev (3m)-33.99%
EPS NQ rev (1m)3.44%
EPS NQ rev (3m)-2.31%
EPS NY rev (1m)-0.61%
EPS NY rev (3m)-13.71%
Revenue NQ rev (1m)3.83%
Revenue NQ rev (3m)-31.57%
Revenue NY rev (1m)-3.69%
Revenue NY rev (3m)-14.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.41
P/FCF N/A
P/OCF N/A
P/B 1.08
P/tB 1.09
EV/EBITDA N/A
EPS(TTM)-8.73
EYN/A
EPS(NY)-8.04
Fwd EYN/A
FCF(TTM)-10.43
FCFYN/A
OCF(TTM)-7.89
OCFYN/A
SpS8.22
BVpS26.04
TBVpS25.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.42%
ROE -33.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.68%
FCFM N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
F-Score5
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 511.46%
Cap/Sales 30.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.22
Quick Ratio 4.14
Altman-Z 3.35
F-Score5
WACC9.91%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.92%
EPS Next Y-12.35%
EPS Next 2Y6.46%
EPS Next 3Y13.02%
EPS Next 5Y18.49%
Revenue 1Y (TTM)-38.35%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-35.33%
Revenue Next Year-34.88%
Revenue Next 2Y-15.76%
Revenue Next 3Y-4.3%
Revenue Next 5Y20.3%
EBIT growth 1Y32.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.67%
EBIT Next 3Y12.82%
EBIT Next 5Y18.31%
FCF growth 1Y-759.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-407.35%
OCF growth 3YN/A
OCF growth 5YN/A